Kidney Cancer - Pipeline Review, H1 2015

Date: June 30, 2015
Pages: 847
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: KA5E01D6512EN
Leaflet:

Download PDF Leaflet

Kidney Cancer - Pipeline Review, H1 2015

SUMMARY

Global Markets Direct’s, ‘Kidney Cancer - Pipeline Review, H1 2015’, provides an overview of the Kidney Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Kidney Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Kidney Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Kidney Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Kidney Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Kidney Cancer Overview
Therapeutics Development
Kidney Cancer - Therapeutics under Development by Companies
Kidney Cancer - Therapeutics under Investigation by Universities/Institutes
Kidney Cancer - Pipeline Products Glance
Kidney Cancer - Products under Development by Companies
Kidney Cancer - Products under Investigation by Universities/Institutes
Kidney Cancer - Companies Involved in Therapeutics Development
Kidney Cancer - Therapeutics Assessment
Drug Profiles
Kidney Cancer - Recent Pipeline Updates
Kidney Cancer - Dormant Projects
Kidney Cancer - Discontinued Products
Kidney Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Kidney Cancer, H1 2015
Number of Products under Development for Kidney Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Kidney Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015
Kidney Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015
Kidney Cancer - Pipeline by Advaxis, Inc., H1 2015
Kidney Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015
Kidney Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015
Kidney Cancer - Pipeline by Altor BioScience Corporation, H1 2015
Kidney Cancer - Pipeline by Ambrx, Inc., H1 2015
Kidney Cancer - Pipeline by Amgen Inc., H1 2015
Kidney Cancer - Pipeline by Amorfix Life Sciences Ltd., H1 2015
Kidney Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Angiogene Pharmaceuticals Limited, H1 2015
Kidney Cancer - Pipeline by APEIRON Biologics AG, H1 2015
Kidney Cancer - Pipeline by arGEN-X BV, H1 2015
Kidney Cancer - Pipeline by Argos Therapeutics, Inc., H1 2015
Kidney Cancer - Pipeline by ArQule, Inc., H1 2015
Kidney Cancer - Pipeline by Astellas Pharma Inc., H1 2015
Kidney Cancer - Pipeline by AstraZeneca Plc, H1 2015
Kidney Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2015
Kidney Cancer - Pipeline by Bayer AG, H1 2015
Kidney Cancer - Pipeline by Beta Pharma, Inc., H1 2015
Kidney Cancer - Pipeline by BIND Therapeutics, Inc., H1 2015
Kidney Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2015
Kidney Cancer - Pipeline by Biogenomics Limited, H1 2015
Kidney Cancer - Pipeline by Bionomics Limited, H1 2015
Kidney Cancer - Pipeline by BioNovion B.V., H1 2015
Kidney Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Kidney Cancer - Pipeline by Boston Biomedical, Inc., H1 2015
Kidney Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015
Kidney Cancer - Pipeline by Caladrius Biosciences, Inc. , H1 2015
Kidney Cancer - Pipeline by Calithera Biosciences, Inc., H1 2015
Kidney Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2015
Kidney Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015
Kidney Cancer - Pipeline by Celltrion, Inc., H1 2015
Kidney Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015
Kidney Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2015
Kidney Cancer - Pipeline by Conkwest, Inc., H1 2015
Kidney Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015
Kidney Cancer - Pipeline by CureTech Ltd., H1 2015
Kidney Cancer - Pipeline by Cytune Pharma SAS, H1 2015
Kidney Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2015
Kidney Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Eli Lilly and Company, H1 2015
Kidney Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Exelixis, Inc., H1 2015
Kidney Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Kidney Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Kidney Cancer - Pipeline by GenSpera, Inc., H1 2015
Kidney Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015
Kidney Cancer - Pipeline by Glycotope GmbH, H1 2015
Kidney Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2015
Kidney Cancer - Pipeline by Hospira, Inc., H1 2015
Kidney Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015
Kidney Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015
Kidney Cancer - Pipeline by immatics biotechnologies GmbH, H1 2015
Kidney Cancer - Pipeline by Immune Design Corp., H1 2015
Kidney Cancer - Pipeline by Immunicum AB, H1 2015
Kidney Cancer - Pipeline by ImmunoGen, Inc., H1 2015
Kidney Cancer - Pipeline by Immunomedics, Inc., H1 2015
Kidney Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Kidney Cancer - Pipeline by Incyte Corporation, H1 2015
Kidney Cancer - Pipeline by Innate Immunotherapeutics Limited, H1 2015
Kidney Cancer - Pipeline by InteRNA Technologies B.V., H1 2015
Kidney Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Johnson & Johnson, H1 2015
Kidney Cancer - Pipeline by KAHR medical Ltd., H1 2015
Kidney Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Kidney Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Mabion SA, H1 2015
Kidney Cancer - Pipeline by MacroGenics, Inc., H1 2015
Kidney Cancer - Pipeline by MediaPharma s.r.l., H1 2015
Kidney Cancer - Pipeline by MediGene AG, H1 2015
Kidney Cancer - Pipeline by MedImmune, LLC, H1 2015
Kidney Cancer - Pipeline by Merck & Co., Inc., H1 2015
Kidney Cancer - Pipeline by Merck KGaA, H1 2015
Kidney Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Mirati Therapeutics Inc., H1 2015
Kidney Cancer - Pipeline by Mologen AG, H1 2015
Kidney Cancer - Pipeline by NewLink Genetics Corporation, H1 2015
Kidney Cancer - Pipeline by Novartis AG, H1 2015
Kidney Cancer - Pipeline by Omeros Corporation, H1 2015
Kidney Cancer - Pipeline by Oncobiologics, Inc., H1 2015
Kidney Cancer - Pipeline by Oncolys BioPharma Inc., H1 2015
Kidney Cancer - Pipeline by OncoMax, H1 2015
Kidney Cancer - Pipeline by Oncothyreon Inc., H1 2015
Kidney Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Panacea Biotec Limited, H1 2015
Kidney Cancer - Pipeline by Panacela Labs, Inc., H1 2015
Kidney Cancer - Pipeline by Peloton Therapeutics, Inc., H1 2015
Kidney Cancer - Pipeline by Pfizer Inc., H1 2015
Kidney Cancer - Pipeline by Pharmicell Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Pivotal BioSciences, Inc., H1 2015
Kidney Cancer - Pipeline by Plexxikon Inc., H1 2015
Kidney Cancer - Pipeline by Pono Pharma, H1 2015
Kidney Cancer - Pipeline by Prima BioMed Ltd., H1 2015
Kidney Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2015
Kidney Cancer - Pipeline by Qu Biologics Inc., H1 2015
Kidney Cancer - Pipeline by Recombio S.L, H1 2015
Kidney Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Sanofi, H1 2015
Kidney Cancer - Pipeline by Seattle Genetics, Inc., H1 2015
Kidney Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Kidney Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2015
Kidney Cancer - Pipeline by TC BioPharm Limited, H1 2015
Kidney Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Kidney Cancer - Pipeline by Theravectys S.A., H1 2015
Kidney Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015
Kidney Cancer - Pipeline by TVAX Biomedical, Inc., H1 2015
Kidney Cancer - Pipeline by Vascular Biogenics Ltd., H1 2015
Kidney Cancer - Pipeline by Vaxeal Holding SA, H1 2015
Kidney Cancer - Pipeline by Welichem Biotech Inc., H1 2015
Kidney Cancer - Pipeline by Zymeworks Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Kidney Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Kidney Cancer - Dormant Projects, H1 2015
Kidney Cancer - Dormant Projects (Contd..1), H1 2015
Kidney Cancer - Dormant Projects (Contd..2), H1 2015
Kidney Cancer - Dormant Projects (Contd..3), H1 2015
Kidney Cancer - Dormant Projects (Contd..4), H1 2015
Kidney Cancer - Dormant Projects (Contd..5), H1 2015
Kidney Cancer - Dormant Projects (Contd..6), H1 2015
Kidney Cancer - Dormant Projects (Contd..7), H1 2015
Kidney Cancer - Dormant Projects (Contd..8), H1 2015
Kidney Cancer - Dormant Projects (Contd..9), H1 2015
Kidney Cancer - Dormant Projects (Contd..10), H1 2015
Kidney Cancer - Dormant Projects (Contd..11), H1 2015
Kidney Cancer - Dormant Projects (Contd..12), H1 2015
Kidney Cancer - Dormant Projects (Contd..13), H1 2015
Kidney Cancer - Dormant Projects (Contd..14), H1 2015
Kidney Cancer - Dormant Projects (Contd..15), H1 2015
Kidney Cancer - Dormant Projects (Contd..16), H1 2015
Kidney Cancer - Dormant Projects (Contd..17), H1 2015
Kidney Cancer - Discontinued Products, H1 2015
Kidney Cancer - Discontinued Products (Contd..1), H1 2015
Kidney Cancer - Discontinued Products (Contd..2), H1 2015
Kidney Cancer - Discontinued Products (Contd..3), H1 2015

LIST OF FIGURES

Number of Products under Development for Kidney Cancer, H1 2015
Number of Products under Development for Kidney Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

COMPANIES MENTIONED

Acceleron Pharma, Inc.
Advanced Cancer Therapeutics
Advaxis, Inc.
Advenchen Laboratories, LLC
Alethia Biotherapeutics Inc.
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
Amorfix Life Sciences Ltd.
Ampio Pharmaceuticals, Inc.
Angiogene Pharmaceuticals Limited
APEIRON Biologics AG
arGEN-X BV
Argos Therapeutics, Inc.
ArQule, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Bayer AG
Beta Pharma, Inc.
BIND Therapeutics, Inc.
Bio-Cancer Treatment International Limited
Biogenomics Limited
Bionomics Limited
BioNovion B.V.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
CASI Pharmaceuticals Inc.
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Conkwest, Inc.
Corcept Therapeutics Incorporated
CureTech Ltd.
Cytune Pharma SAS
Ecrins Therapeutics SAS
Eisai Co., Ltd.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
GlaxoSmithKline Plc
Glycotope GmbH
Hemispherx Biopharma, Inc.
Hospira, Inc.
Hutchison MediPharma Limited
Ildong Pharmaceutical Co., Ltd.
immatics biotechnologies GmbH
Immune Design Corp.
Immunicum AB
ImmunoGen, Inc.
Immunomedics, Inc.
Inbiopro Solutions Pvt. Ltd.
Incyte Corporation
Innate Immunotherapeutics Limited
InteRNA Technologies B.V.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
KAHR medical Ltd.
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Mabion SA
MacroGenics, Inc.
MediaPharma s.r.l.
MediGene AG
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mologen AG
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncobiologics, Inc.
Oncolys BioPharma Inc.
OncoMax
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
Panacea Biotec Limited
Panacela Labs, Inc.
Peloton Therapeutics, Inc.
Pfizer Inc.
Pharmicell Co., Ltd.
Pivotal BioSciences, Inc.
Plexxikon Inc.
Pono Pharma
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Qu Biologics Inc.
Recombio S.L
Rexahn Pharmaceuticals, Inc.
Sanofi
Seattle Genetics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syndax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
TC BioPharm Limited
Teva Pharmaceutical Industries Limited
Theravectys S.A.
Threshold Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Vascular Biogenics Ltd.
Vaxeal Holding SA
Welichem Biotech Inc.
Zymeworks Inc.
Skip to top


Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 50 pages
Oropharyngeal Cancer - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 136 pages
Gastric Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 962 pages
Esophageal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 448 pages

Ask Your Question

Kidney Cancer - Pipeline Review, H1 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: